PCOS and peripheral AMH levels in relation to FSH receptor gene single nucleotide polymorphisms

被引:17
作者
Mohiyiddeen, Lamiya [2 ]
Salim, Serena [2 ]
Mulugeta, Betselot [2 ]
McBurney, Helen
Newman, William G.
Pemberton, Phil [4 ]
Nardo, Luciano G. [1 ,3 ]
机构
[1] GyneHealth, Reprod Med & Surg Unit, Manchester M3 4DN, Lancs, England
[2] St Marys Hosp, Dept Reprod Med, Manchester M13 0JH, Lancs, England
[3] Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Maternal & Fetal Hlth Res Grp, Manchester M13 0JH, Lancs, England
[4] Manchester Royal Infirm, Dept Clin Biochem, Manchester M13 9WL, Lancs, England
关键词
Anti-mullerian hormone; FSH receptor; ovulation induction; PCOS; single nucleotide polymorphism; Ser680Asn; POLYCYSTIC-OVARY-SYNDROME; ANTI-MULLERIAN HORMONE; WOMEN;
D O I
10.3109/09513590.2011.633649
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To determine if an association exists between the follicle-stimulating hormone receptor (FSHR) gene p.Asn680Ser polymorphism and polycystic ovary syndrome (PCOS) or with high anti-mullerian hormone (AMH) levels without PCOS. Patients: Fifty-eight women with PCOS, 24 women with high AMH (>44.5 pmol/L) without PCOS and 80 healthy ethnically matched female controls. Main outcome measures: Prevalence of the FSHR p.Asn680Ser polymorphism, baseline serum AMH levels and response to ovulation induction with clomiphene citrate. Results: The frequency of FSHR p.Asn680Ser genotypes were not significantly different between PCOS patients, patients with high AMH without PCOS and controls (p = 0.88). Of the women with PCOS, 34/58 were on clomiphene citrate treatment and 12/34 were resistant. There was no association between sensitivity or resistance to clomiphene and p.Asn680Ser genotypes (p = 0.38). Conclusions: There is no evidence that FSHR p.Asn680Ser genotypes are associated with PCOS, high AMH levels or response to clomiphene citrate.
引用
收藏
页码:375 / 377
页数:3
相关论文
共 17 条
[1]  
[Anonymous], 1973, World Health Organ Tech Rep Ser, V527, P1
[2]   Oligoovulatory and Anovulatory Cycles in Women with Polycystic Ovary Syndrome (PCOS): What's the Difference? [J].
Burgers, Janneke A. ;
Fong, Sharon Lie ;
Louwers, Yvonne V. ;
Valkenburg, Olivier ;
de Jong, Frank H. ;
Fauser, Bart C. J. M. ;
Laven, Joop S. E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (12) :E485-E489
[3]   Anti-Mullerian Hormone, Its Receptor, FSH Receptor, and Androgen Receptor Genes Are Overexpressed by Granulosa Cells from Stimulated Follicles in Women with Polycystic Ovary Syndrome [J].
Catteau-Jonard, Sophie ;
Jamin, Soazik P. ;
Leclerc, Arnaud ;
Gonzales, Jacques ;
Dewailly, Didier ;
di Clemente, Nathalie .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (11) :4456-4461
[4]   Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome [J].
Conway, GS ;
Conway, E ;
Walker, C ;
Hoppner, W ;
Gromoll, J ;
Simoni, M .
CLINICAL ENDOCRINOLOGY, 1999, 51 (01) :97-99
[5]   Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome [J].
Das, M. ;
Gillott, D. J. ;
Saridogan, E. ;
Djahanbakhch, O. .
HUMAN REPRODUCTION, 2008, 23 (09) :2122-2126
[6]   Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary [J].
Durlinger, ALL ;
Gruijters, MJG ;
Kramer, P ;
Karels, B ;
Ingraham, HA ;
Nachtigal, MW ;
Uilenbroek, JTJ ;
Grootegoed, JA ;
Themmen, APN .
ENDOCRINOLOGY, 2002, 143 (03) :1076-1084
[7]   Medical progress: Polycystic ovary syndrome [J].
Ehrmann, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (12) :1223-1236
[8]   Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Guibourdenche, J ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :323-327
[9]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J].
Fauser, BCJM ;
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
HUMAN REPRODUCTION, 2004, 19 (01) :41-47
[10]   'Drug reactions, enzymes, and biochemical genetics': 50 years later [J].
Gurwitz, David ;
Motulsky, Arno G. .
PHARMACOGENOMICS, 2007, 8 (11) :1479-1484